论文部分内容阅读
目的:比较两种降尿酸药物(别嘌呤醇和苯溴马隆)治疗慢性心力衰竭(CHF)伴高尿酸血症患者改善心功能的效果。方法:选择伴高尿酸血症的CHF患者60例,随机分为3组,每组20例,接受常规治疗的为常规治疗组,在常规治疗基础上加服别嘌呤醇的为别嘌呤醇组,加服苯溴马隆者的为苯溴马隆组。治疗6个月后,对比各组血尿酸、左室射血分数(LVEF)、左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)治疗前后的变化。结果:别嘌呤醇组和苯溴马隆组降低尿酸的效果相当;和常规治疗组相比别嘌呤醇组对心功能的改善更显著(P<0.05),而苯溴马隆组与常规治疗组的差异无统计学意义。结论:抑制黄嘌呤氧化酶的别嘌呤醇对改善CHF患者心功能的作用优于单纯排尿酸的苯溴马隆。
Objective: To compare the effects of two uric acid lowering drugs (allopurinol and benzbromarone) on improving cardiac function in patients with chronic heart failure (CHF) and hyperuricemia. Methods: Sixty CHF patients with hyperuricemia were randomly divided into 3 groups (20 in each group). All patients undergoing routine treatment were treated with conventional therapy. Allopurinol group was treated with allopurinol , Add benzbromarone for benzbromarone group. After 6 months of treatment, changes of serum uric acid, left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD) and left ventricular end-systolic diameter (LVESD) were compared before and after treatment. Results: Allopurinol group and benzbromarone group had similar effect of lowering uric acid. Compared with conventional treatment group, allopurinol group had more significant improvement on cardiac function (P <0.05), while benzbromarone group and conventional treatment There was no significant difference between groups. CONCLUSION: Allopurinol, which inhibits xanthine oxidase, is superior to benzbromarone, a simple uricosuric acid, in improving cardiac function in CHF patients.